RxDoctor Payments DataLook up a doctor →

Adam Wolff, MD

Neurology · Denver, CONPI 1053349597

Payments from drug & device makers

$2,396,155in general payments, 2019–2025

Across 2,841 payments — averaging $843.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.1M
  • Novartis$763K
  • Eisai Inc.$199K
  • AbbVie$142K
  • Lilly USA, LLC$81K
  • Sanofi$23K
  • plus $93K from 54 others
$13,471in research payments, 2019–2025

Across 6 payments — averaging $2245.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$13K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly18$1,094,169
Novartis157$763,241
Eisai Inc.239$198,978
AbbVie(2 entities)423$141,615
Lilly USA, LLC185$81,059
Sanofi53$22,526
Biogen133$18,115
E.r. Squibb & Sons, L.L.C.25$15,079
Bristol Myers Squibb119$12,056
Avanir Pharmaceuticals, Inc.6$8,576
Neurocrine Biosciences, Inc.133$8,368
SK Life Science, Inc.52$4,183
UCB, Inc.90$2,315
CSL Behring19$2,192
Acadia Pharmaceuticals Inc77$1,468
Amgen(2 entities)52$1,458
Genentech USA, Inc.52$1,179
MDD US Operations, LLC66$1,173
Teva Pharmaceuticals USA, Inc.89$1,172
EMD Serono, Inc.64$1,166
Pfizer73$1,132
AstraZeneca(2 entities)46$1,114
Merz Pharmaceuticals, LLC57$1,015
Neuronetics, Inc.3$912
Lundbeck LLC48$867
Neurelis, Inc.29$701
Argenx US, Inc.30$593
TG Therapeutics, Inc.26$590
Ipsen Biopharmaceuticals, Inc28$559
Acorda Therapeutics, Inc20$496
Jazz Pharmaceuticals Inc.15$495
Biohaven Pharmaceuticals, Inc.20$481
Sunovion Pharmaceuticals Inc.37$439
Tanabe Pharma America, Inc.23$425
GRT US Holding, Inc.29$333
Otsuka Pharmaceutical Development & Commercialization, Inc.2$295
Mallinckrodt Hospital Products Inc.18$283
Biohaven Pharmaceutical Holding Company Ltd.21$275
Grifols USA, LLC14$275
Supernus Pharmaceuticals, Inc.18$265
Mallinckrodt Enterprises LLC22$264
Livanova USA, Inc.7$249
Amneal Pharmaceuticals LLC15$219
Abbott10$207
ANI Pharmaceuticals, Inc.16$202
Johnson & Johnson(2 entities)10$191
Vanda Pharmaceuticals Inc.7$179
Kyowa Kirin, Inc.7$151
Merz North America, Inc.5$145
Octapharma USA, Inc.6$139
Catalyst Pharmaceuticals, Inc.7$138
Akcea Therapeutics, Inc.9$134
Sobi, Inc7$122
Otsuka America Pharmaceutical, Inc.7$121
Alnylam Pharmaceuticals Inc.5$120
Axsome Therapeutics, Inc.2$116
Microtransponder, Inc.1$116
Upsher-smith Laboratories LLC5$106
Sumitomo Pharma America, Inc.9$103
Adamas Pharmaceuticals, Inc.5$97

How this compares

$2,396,155 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado →

Medicare billing

Part B allowed, 2024
$693,314
Medicare patients
759
Services billed
51,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Denver

See the full list for Colorado →

Where these figures come from

Is this you, or does something look wrong? →